We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eloxx Pharmaceuticals Inc | NASDAQ:ELOX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.82 | 3.60 | 3.75 | 0 | 01:00:00 |
From Jul 2021 to Jul 2024
By Michael Dabaie
Eloxx Pharmaceuticals Inc. Thursday said the U.S. Food and Drug Administration gave fast track designation for ELX-02.
ELX-02 is a drug candidate intended to treat cystic fibrosis patients with nonsense mutations. ELX-02 is currently in Phase 2 clinical trials in CF patients affected by nonsense mutations in the CF transmembrane conductance regulator gene for whom there are no effective disease modifying therapies.
Shares were up 6% to $1.47 in premarket trading.
FDA grants fast track designation to drugs being developed for the treatment of serious or life-threatening diseases or conditions where there is an unmet medical need. Sponsors of drugs that receive fast track designation have the opportunity for more frequent interactions with the FDA review team throughout the development program.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 09, 2021 09:06 ET (13:06 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Eloxx Pharmaceuticals Chart |
1 Month Eloxx Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
